Aspira Women's Health Files 8-K for Equity Sale

TL;DR

Aspira Women's Health selling more stock, filing shows.

AI Summary

On March 5, 2025, Aspira Women's Health Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas.

Why It Matters

This filing indicates a potential capital raise or issuance of new shares, which could impact the company's financial structure and shareholder equity.

Risk Assessment

Risk Level: medium — Filings related to unregistered equity sales can indicate financial needs or strategic shifts that may carry inherent risks for investors.

Key Players & Entities

• Aspira Women's Health Inc. (company) — Registrant
• Vermillion, Inc. (company) — Former Company Name
• Ciphergen Biosystems Inc (company) — Former Company Name
• Abiotic Systems (company) — Former Company Name
• March 5, 2025 (date) — Earliest Event Reported

FAQ

From the Filing

0001493152-25-009784.txt : 20250311 0001493152-25-009784.hdr.sgml : 20250311 20250311080525 ACCESSION NUMBER: 0001493152-25-009784 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20250305 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250311 DATE AS OF CHANGE: 20250311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 25725904 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 form8-k.htm false 0000926617 0000926617 2025-03-05 2025-03-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       Form 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): March 5, 2025       Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter)       Delaware   001-34810   33-0595156 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)   12117 Bee Caves Road , Building III , Suite 100 , Austin , Texas   78738 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: (512) 519-0400       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:  Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWH   Nasdaq Capital Market  Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 1.01 Entry into a Material Definitive Agreement.   On March 5, 2025, Aspira Women’s Health, Inc. (the “Company”)